Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Dobutamine Articles

Santhera publishes results of DMD trial

6 October 2008

Nicholas Piramal gets Lilly's Dobutrex

16 August 2004

War, terror and terroism overshadow normally sanguine FDLI meeting

21 April 2003

Actelion well-placed for success with endothelin antagonists for heart

21 September 2000

Orion's Simdax: 43% mortality reduction

3 September 1999

Blow to Scios and Bayer as FDA seeks more data on Natrecor in heart failure

28 April 1999

First new congestive heart failure therapy for a decade recommended for

3 February 1999

Scios' Natrecor can replace the use of intravenous vasodilators, IV

26 November 1998

Scios' Natrecor Beats Dobutamine

21 September 1998

Cypros' Minimalist Strategy Shows Promise In Ischemia

24 June 1997

Upjohn And Gensia Revamp Oncolytics Deal

23 October 1995

Gensia Launches Arbutamine In UK

12 June 1995

New Dobutamine Regimen Improves Efficacy

13 March 1995

RECALL HITS 1st-QTR NET PROFITS AT LILLY

25 April 1994

EXTENSION TO JAPANESE FORMULARY

11 October 1993

ADVANCES BY US DRUG COMPANIES IN 2nd QTR

26 July 1993

US RESULTS 3RD QTR

2 November 1992

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS